What are the indications, dosing regimen, monitoring requirements, contraindications, and adverse effect management for warfarin?

Warfarin Overview

Warfarin is a vitamin K antagonist anticoagulant used to prevent and treat thromboembolic conditions, requiring meticulous INR monitoring with a target range of 2.0-3.0 for most indications, though mechanical mitral valves require 2.5-3.5. 1

Primary Indications

Warfarin is FDA-approved for:

• Venous thromboembolism (VTE): Prophylaxis and treatment of deep vein thrombosis and pulmonary embolism
• Atrial fibrillation: Prevention of stroke and systemic embolism, particularly in high-risk patients (age >75, prior stroke/TIA, heart failure, hypertension, or diabetes)
• Mechanical heart valves: All patients with mechanical prosthetic valves require warfarin
• Post-myocardial infarction: Reduces risk of death, recurrent MI, and thromboembolic events 1

Dosing Strategy

Initial Dosing

Start with 2-5 mg daily—avoid loading doses as they increase hemorrhagic complications without providing faster protection. 1 Lower initial doses (2 mg) should be used in:

• Elderly patients (≥75 years require approximately 1 mg/day less than younger patients)
• Patients with genetic variations in CYP2C9 or VKORC1
• Debilitated patients
• Those expected to have exaggerated INR responses 1

Maintenance Dosing

Most patients stabilize on 2-10 mg daily. Adjust doses by 5-20% of the total weekly dose based on INR results, not by making large single-dose changes. 2 Dose adjustments should not be made for a single slightly out-of-range INR unless there are clinical concerns.

Duration by Indication

• First VTE with transient risk factor: 3 months
• First idiopathic VTE: 6-12 months minimum
• Recurrent VTE (≥2 episodes): Indefinite therapy
• Mechanical heart valves: Lifelong
• Atrial fibrillation with stroke risk factors: Typically indefinite 1

Target INR Ranges

The therapeutic target varies by indication:

• Standard (most indications): INR 2.0-3.0

  • VTE treatment and prophylaxis
  • Atrial fibrillation
  • St. Jude bileaflet valve in aortic position
  • Bioprosthetic valves (first 3 months)

• Higher intensity: INR 2.5-3.5

  • Mechanical mitral valves
  • Tilting disk valves
  • Caged ball or caged disk valves (add aspirin 75-100 mg/day) 1

INR >4.0 provides no additional benefit and significantly increases bleeding risk. 1

Monitoring Requirements

Frequency

• Initial phase: Daily INR until stable in therapeutic range
• Dose adjustment phase: 2-4 times weekly
• Stable maintenance: Every 1-4 weeks (maximum 4-6 weeks between tests) 1

Increase monitoring frequency when:

• Starting or stopping interacting medications
• Patient takes medications irregularly
• Switching warfarin formulations
• Any change in clinical status 1

Managing Elevated INR

The approach depends on INR level and bleeding status 3:

INR >Therapeutic but <5 (No Bleeding)

• Reduce or omit next dose
• Resume at lower dose when INR approaches therapeutic range
• No vitamin K needed

INR 5-9 (No Bleeding, Low Bleeding Risk)

• Omit 1-2 doses
• Resume at lower dose when therapeutic
• If high bleeding risk: Give oral vitamin K₁ 1-2.5 mg

INR 5-9 (Urgent Surgery Needed)

• Oral vitamin K₁ 2-5 mg
• Expect INR reduction within 24 hours
• Additional 1-2 mg if still elevated at 24 hours

INR ≥9 (No Active Bleeding)

• Oral vitamin K₁ 3-5 mg
• Expect INR fall within 24-48 hours
• Monitor closely and repeat as needed

Serious Bleeding or INR ≥20

• IV vitamin K₁ 10 mg by slow infusion (over 30 minutes)
• Plus fresh frozen plasma or prothrombin complex concentrate
• Repeat vitamin K₁ every 12 hours as needed

Life-Threatening Bleeding

• Prothrombin complex concentrate (4-factor preferred)
• Plus IV vitamin K₁ 10 mg
• Repeat based on INR 3, 4

Critical point: Oral vitamin K₁ is preferred over subcutaneous (which has unpredictable absorption) and is safer than IV (which carries anaphylaxis risk). Use the injectable formulation given orally when oral vitamin K₁ is indicated. 3

Major Adverse Effects

Bleeding Risk Factors

Bleeding is the primary complication, with risk proportional to INR intensity. Additive risk factors include:

• Age ≥65 years (elderly are more prone even at therapeutic INR)
• Prior stroke or GI bleeding
• Renal insufficiency or anemia
• Concomitant antiplatelet agents (aspirin, NSAIDs)
• Multiple risk factors compound exponentially 3

Bleeding at INR ≤3.0 usually indicates underlying pathology (GI lesion, trauma) requiring investigation. 3

Non-Hemorrhagic Complications

Warfarin-induced skin necrosis (days 3-8 of therapy):

• Associated with protein C deficiency but occurs in normal patients
• Presents as extensive venous thrombosis in subcutaneous fat
• Management: Stop warfarin; restart at very low dose (2 mg) under therapeutic heparin coverage, increase gradually over ≥1 week 5

Purple toe syndrome:

• Cholesterol emboli occurring 3-8 weeks after initiation
• Bilateral painful purple lesions on toes/feet that blanch with pressure 5

Contraindications

Absolute

• Active major bleeding
• Pregnancy (first trimester causes embryopathy; later trimesters cause CNS abnormalities and fetal bleeding)
• Severe bleeding diathesis
• Recent or planned CNS/eye surgery

Relative (Requires Risk-Benefit Analysis)

• Recent major trauma or surgery
• Active peptic ulcer disease
• Severe uncontrolled hypertension
• High fall risk
• Poor medication adherence or inability to monitor INR 3, 6

Perioperative Management

The strategy depends on thrombotic risk 3:

Low Thrombotic Risk (e.g., atrial fibrillation alone)

• Stop warfarin 4-5 days preoperatively
• INR will normalize by surgery
• Resume maintenance dose postoperatively with low-dose heparin bridge if needed

Moderate Risk

• Stop warfarin 4-5 days before
• Start prophylactic-dose heparin/LMWH (5000 U SC q12h)
• Restart both 12 hours postoperatively until INR therapeutic

High Risk (mechanical valves, recent VTE)

• Stop warfarin 4-5 days before
• Therapeutic-dose heparin (15,000 U SC q12h) or LMWH (100 U/kg SC q12h)
• Stop 24 hours before surgery
• Resume prophylactic doses 12 hours postoperatively with warfarin

Alternative for Rapid Reversal

• Give oral vitamin K₁ 2.5 mg two days before procedure
• Reduces unprotected time to 2 days

For dental procedures: Use tranexamic acid or ε-aminocaproic acid mouthwash without interrupting warfarin. 3

Surgery can proceed safely with INR ≤1.5. 7

Critical Drug Interactions

Warfarin has extensive pharmacokinetic (affecting metabolism) and pharmacodynamic (affecting bleeding risk) interactions:

Increased Bleeding Risk

• Antiplatelet agents (aspirin, clopidogrel)
• NSAIDs (also cause GI erosions)
• Antibiotics (especially metronidazole, trimethoprim, fluoroquinolones)
• Amiodarone
• Azole antifungals

Decreased Anticoagulation

• Rifampin
• Carbamazepine
• Vitamin K-containing foods (inconsistent intake)

Monitor INR closely when starting, stopping, or changing doses of any medication. 1, 6

Special Populations

Pregnancy

Warfarin is contraindicated throughout pregnancy. Use heparin or LMWH instead, though LMWH is not FDA-approved for mechanical valve thromboprophylaxis. 3

Elderly

Require lower doses (typically 1 mg/day less) and have higher bleeding risk independent of INR. Start with 2 mg daily. 3, 1

Genetic Considerations

CYP2C9 and VKORC1 polymorphisms affect warfarin sensitivity. Asian populations generally require lower doses than Western populations. 8

Quality Metrics

Time in therapeutic range (TTR) should exceed 60-70%. Patients with TTR <60% have increased risk of both thrombotic and bleeding complications. Poor TTR warrants investigation of adherence, drug interactions, dietary factors, or consideration of alternative anticoagulation. 9